Qube Research & Technologies LTD Eagle Pharmaceuticals, Inc. Transaction History

Qube Research & Technologies LTD

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$3.34 - $5.6 $44,128 - $73,987	13,212 Added 372.06%	16,763 $93,000
Q1 2024 May 14, 2024	SELL	$4.26 - $6.51 $52,380 - $80,046	-12,296 Reduced 77.59%	3,551 $18,000
Q4 2023 Feb 13, 2024	SELL	$4.63 - $15.21 $8,968 - $29,461	-1,937 Reduced 10.89%	15,847 $82,000
Q3 2023 Nov 13, 2023	SELL	$15.21 - $22.88 $221,944 - $333,864	-14,592 Reduced 45.07%	17,784 $280,000
Q2 2023 Aug 14, 2023	BUY	$17.74 - $31.87 $65,052 - $116,867	3,667 Added 12.77%	32,376 $629,000
Q1 2023 May 15, 2023	SELL	$25.06 - $34.09 $93,273 - $126,882	-3,722 Reduced 11.48%	28,709 $814,000
Q4 2022 Feb 14, 2023	SELL	$24.98 - $39.77 $147,357 - $234,603	-5,899 Reduced 15.39%	32,431 $947,000
Q3 2022 Nov 14, 2022	BUY	$26.42 - $47.12 $1.01 Million - $1.81 Million	38,330 New	38,330 $1.01 Million
Q2 2022 Aug 15, 2022	SELL	$41.26 - $51.35 $295,339 - $367,563	-7,158 Closed	0 $0
Q1 2022 May 09, 2022	SELL	$44.58 - $52.6 $117,468 - $138,601	-2,635 Reduced 26.91%	7,158 $354,000
Q4 2021 Feb 01, 2022	BUY	$45.82 - $56.9 $448,715 - $557,221	9,793 New	9,793 $499,000
Q2 2021 Aug 13, 2021	SELL	$36.86 - $44.5 $248,030 - $299,440	-6,729 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$40.32 - $50.97 $48,746 - $61,622	1,209 Added 21.9%	6,729 $281,000
Q4 2020 Feb 16, 2021	BUY	$41.72 - $51.34 $230,294 - $283,396	5,520 New	5,520 $257,000

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.